sofosbuvir + efavirenz + zidovudine + lamivudine

sofosbuvir + efavirenz + zidovudine + lamivudine is a quadruple antiretroviral combination that includes **sofosbuvir** (a nucleotide analog inhibitor of hepatitis C virus NS5B polymerase) and three anti-HIV agents: **efavirenz** (a non-nucleoside reverse transcriptase inhibitor), **zidovudine**, and **lamivudine** (both nucleoside analog reverse transcriptase inhibitors). This combination is not available as a single, branded fixed-dose product; however, each component is marketed individually or as dual/triple combinations for the treatment of HIV or HCV. - **Sofosbuvir** targets hepatitis C virus by directly inhibiting viral RNA replication. - **Efavirenz, zidovudine, and lamivudine** act by inhibiting HIV-1 reverse transcriptase at different sites, thereby blocking viral replication and slowing progression of HIV infection[1][4][3]. This quadruple combination may be considered in rare clinical scenarios where co-infection (HIV/HCV) is present, but there is little published evidence or regulatory approval for its use as a single regimen. Primary indications: chronic hepatitis C (sofosbuvir), HIV-1 infection (efavirenz, zidovudine, lamivudine).